TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8543620

Group type: EXPERIMENTAL
Intervention: Flow cytometry analysis for FMH quantitation
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Flow cytometry analysis leading to anti-D immunoglobulin administration
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Follow-up testing for immunisation
Number of subjects: 43
Study: 2227107

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice daily)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Nifedipine AR (20 mg twice daily)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (1 tablet twice daily)
Number of subjects: 64
Study: 415359

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cromolyn (Lomudal)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no placebo)
Number of subjects: 15
Study: 30635033

Group type: EXPERIMENTAL
Intervention: Clazakizumab (subcutaneous administration of 25 mg in monthly intervals)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 25439076

Group type: EXPERIMENTAL
Intervention: Sleep duration 7 to <8 hours
Number of subjects: 391

Group type: COMPARATOR
Intervention: Sleep duration <6 hours
Number of subjects: 391

Group type: COMPARATOR
Intervention: Sleep duration ≥9 hours
Number of subjects: 391
Study: 22765511

Group type: COMPARATOR
Intervention: Conventional brackets
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Self-ligating brackets
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both bracket types
Number of subjects: 38
Study: 21386797

Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Diet (VLCD)
Number of subjects: 24
Study: 19317863

Group type: EXPERIMENTAL
Intervention: Bupivacaine with 0.5 microg/kg neostigmine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bupivacaine with 0.75 microg/kg neostigmine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bupivacaine with 1 microg/kg neostigmine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Plain 0.5% hyperbaric bupivacaine
Number of subjects: 75
Study: 16740529

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass surgery
Number of subjects: 168

Group type: COMPARATOR
Intervention: Conventional coronary artery bypass grafting surgery using cardiopulmonary bypass
Number of subjects: 168
Study: 15250864

Group type: EXPERIMENTAL
Intervention: Ventricular triad (RV ‐‐> SVC + Can)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Unipolar (RV ‐‐> Can)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Proximal triad (SVC ‐‐> RV + Can)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Proximal triad
Number of subjects: 58
Study: 11262468

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 7
Study: 9305202

Group type: EXPERIMENTAL
Intervention: Normothermic perfusion (37 degrees C)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Hypothermia (28 degrees C)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Moderate hypothermia (32 degrees C)
Number of subjects: 300
Study: 8359292

Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (ASA, 75 mg daily)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo (identical tablets)
Number of subjects: 232
Study: 3521832

Group type: EXPERIMENTAL
Intervention: 3,150 rads of preoperative radiotherapy
Number of subjects: 361

Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: First preoperative radiotherapy trial
Number of subjects: 361

Group type: COMPARATOR
Intervention: First preoperative radiotherapy trial (Control)
Number of subjects: 361
Study: 29371264

Group type: EXPERIMENTAL
Intervention: Nurse-supported self-management programme
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 89
Study: 27247434

Group type: EXPERIMENTAL
Intervention: COBRA (prednisolone 60 mg/day, tapered to 7.5 mg/day in 6 weeks; MTX and SSZ)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: COBRA-light therapy (prednisolone 30 mg/day, tapered to 7.5 mg/day in 8 weeks and MTX)
Number of subjects: 108
Study: 26291644

Group type: EXPERIMENTAL
Intervention: Qualitative projective story‐telling technique (Düss Fable)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative data (Child Behaviour Checklist)
Number of subjects: 0
Study: 23317049

Group type: EXPERIMENTAL
Intervention: SCTG plus EMD
Number of subjects: 42

Group type: COMPARATOR
Intervention: SCTG
Number of subjects: 42
Study: 21134017

Group type: EXPERIMENTAL
Intervention: Caffeinated alcoholic beverage (69 mg caffeine/12 oz beer)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Non-caffeinated alcoholic beverage
Number of subjects: 127
Study: 19052516

Group type: EXPERIMENTAL
Intervention: Bioengineered skin substitutes with a dermal component
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 16750341

Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound technique (QUS) at the phalanges
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (non-dialytic and non-fractured women)
Number of subjects: 73
Study: 12875936

Group type: EXPERIMENTAL
Intervention: Flutamide or Cyproterone acetate
Number of subjects: 257
Study: 11853591

Group type: EXPERIMENTAL
Intervention: Phacotrabeculectomy with IOL implantation
Number of subjects: 68

Group type: COMPARATOR
Intervention: ECCE, trabeculectomy and IOL implantation
Number of subjects: 68
Study: 9092738

Group type: EXPERIMENTAL
Intervention: Capsaicin 0.025% cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1487551

Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg three times daily for 3 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acute volume expansion (1500 mL saline in 15 minutes, in supine legs-up position)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verapamil with volume expansion
Number of subjects: 0
Study: 3021488

Group type: COMPARATOR
Intervention: Nedocromil sodium (4 mg) q.i.d.
Number of subjects: 167

Group type: COMPARATOR
Intervention: Nedocromil sodium (4 mg) b.i.d.
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 167
Study: 31186047

Group type: EXPERIMENTAL
Intervention: Oleogel-S10
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28315450

Group type: EXPERIMENTAL
Intervention: Carotenoid supplementation (Macushield™: 10 mg meso-zeaxanthin, 10 mg lutein, 2 mg zeaxanthin)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (sunflower oil)
Number of subjects: 37
Study: 25824243

Group type: EXPERIMENTAL
Intervention: rhGH (47.6-52.4 μg/kg/day) and low-dose stanozolol (20-35 μg/kg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 44
Study: 24317497

Group type: EXPERIMENTAL
Intervention: Web-based psychoeducational program (Diapason), 12 weeks duration, weekly sessions
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care (Control condition)
Number of subjects: 80
Study: 22310865

Group type: EXPERIMENTAL
Intervention: Interpersonal relationship program (10 sessions over 10 weeks, 90 minutes each)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 64
Study: 19484836

Group type: EXPERIMENTAL
Intervention: Vascular care (treatment according to strict guidelines for hypercholesterolemia and hypertension, including acetylsalicylic acid, folic acid, and pyridoxine)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Vascular care
Number of subjects: 130
Study: 17251237

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP (in CPAP-compliant patients)
Number of subjects: 34
Study: 15027793

Group type: EXPERIMENTAL
Intervention: Free association task
Number of subjects: 41

Group type: COMPARATOR
Intervention: Describing most stressful life experience
Number of subjects: 41
Study: 14709288

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2% drops 2 times a day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 40
Study: 9640158

Group type: EXPERIMENTAL
Intervention: Thiopental 5 mg kg‐1 (AT‐R group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg kg‐1 (AE‐R group)
Number of subjects: 60
Study: 7569161

Group type: EXPERIMENTAL
Intervention: External cephalic version with tocolysis
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 3055394

Group type: EXPERIMENTAL
Intervention: Perioperative parenteral cefoxitin (Group A)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Preoperative oral neomycin and erythromycin plus perioperative cefoxitin (Group B)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Group A (cefoxitin) with rectal resections
Number of subjects: 350

Group type: COMPARATOR
Intervention: Group B (neomycin and erythromycin plus cefoxitin) with rectal resections
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Group A (cefoxitin) with intraperitoneal colon resection
Number of subjects: 350

Group type: COMPARATOR
Intervention: Group B (neomycin and erythromycin plus cefoxitin) with intraperitoneal colon resection
Number of subjects: 350

Group type: COMPARATOR
Intervention: Group B patients with longer rectal operations
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Group A patients with longer rectal operations
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Patients with rectal resection and operative times of 215 minutes or more
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Patients with shorter nonrectal operations
Number of subjects: 350

Group type: COMPARATOR
Intervention: Group B patients
Number of subjects: 350
Study: 4592210

Group type: EXPERIMENTAL
Intervention: Positive end expiratory pressure (PEEP) of 10 cm H2O added to intermittent positive pressure ventilation (IPPV)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intermittent positive pressure ventilation (IPPV) without PEEP
Number of subjects: 8
Study: 31124422

Group type: EXPERIMENTAL
Intervention: In-person follow-up group (IN-FU), n=200
Number of subjects: 400

Group type: COMPARATOR
Intervention: Telephone follow-up group (TEL-FU), n=200
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 400
Study: 30920631

Group type: EXPERIMENTAL
Intervention: Streptococcus salivarius 24SMB and Streptococcus oralis 89a nasal spray, 2 puffs per nostril twice a day for a week for 3 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Hypertonic saline nasal lavage
Number of subjects: 44
Study: 29042389

Group type: EXPERIMENTAL
Intervention: Trainees
Number of subjects: 1749

Group type: COMPARATOR
Intervention: Consultants
Number of subjects: 1749

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1749
Study: 25425002

Group type: EXPERIMENTAL
Intervention: RT-ATM
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: RT-LTM
Number of subjects: 47

Group type: COMPARATOR
Intervention: RT
Number of subjects: 47
Study: 23925369

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 24
Study: 21125336

Group type: EXPERIMENTAL
Intervention: uPA system gene polymorphisms (specifically PAI-1 gene)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Environmental carcinogens (betel nut and tobacco consumption)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: uPAR gene polymorphism
Number of subjects: 253
Study: 20465019

Group type: EXPERIMENTAL
Intervention: Novel nasal EPAP device
Number of subjects: 34
Study: 17123215

Group type: EXPERIMENTAL
Intervention: Specific intervention programme for endurant pain coping behavior (n = 163)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Standard programme of an orthopaedic rehabilitation clinic (n = 252)
Number of subjects: 415
Study: 15016040

Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing (FM-SRP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Quadrant scaling and root planing (Q-SRP)
Number of subjects: 40
Study: 11323362

Group type: EXPERIMENTAL
Intervention: Epidural infusion of ropivacaine 2 mg/mL with fentanyl 2 microg/mL (R + F)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Epidural infusion of ropivacaine 2 mg/mL without fentanyl (R)
Number of subjects: 155
Study: 9302489

Group type: EXPERIMENTAL
Intervention: Exercise (EX; 20 min of cycling at 60% estimated VO2max)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal workstation duties for 60 min (WRK)
Number of subjects: 28

Group type: COMPARATOR
Intervention: 60 min sedentary lunch break (SED)
Number of subjects: 28
Study: 8394796

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg administered at 7 AM
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg administered at 7 PM
Number of subjects: 8
Study: 3205554

Group type: EXPERIMENTAL
Intervention: 2% lidocaine (xylocaine) containing 1:80,000 epinephrine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3% prilocaine (Citanest) containing 0.03 IU/ml felypressin
Number of subjects: 12
Study: 31158553

Group type: EXPERIMENTAL
Intervention: tDCS plus FES
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham tDCS plus FES
Number of subjects: 30
Study: 29583063

Group type: EXPERIMENTAL
Intervention: Single-pass pulsed dye laser (SWL)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Double-pass pulsed dye laser (DWL)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 21
Study: 28468736

Group type: EXPERIMENTAL
Intervention: Nicotinamide 500 mg/daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no nicotinamide)
Number of subjects: 38
Study: 25727519

Group type: EXPERIMENTAL
Intervention: Fibular taping with tension
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fibular taping without tension
Number of subjects: 21
Study: 23816035

Group type: EXPERIMENTAL
Intervention: Educational video intervention
Number of subjects: 59

Group type: COMPARATOR
Intervention: Usual care (health care provider counseling)
Number of subjects: 59
Study: 21435142

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 130
Study: 18492867

Group type: EXPERIMENTAL
Intervention: Intensive renal-replacement therapy (intermittent hemodialysis six times per week, sustained low-efficiency dialysis, continuous venovenous hemodiafiltration at 35 ml/kg/hour)
Number of subjects: 1124

Group type: COMPARATOR
Intervention: Less-intensive renal-replacement therapy (intermittent hemodialysis three times per week, continuous renal-replacement therapy at 20 ml/kg/hour)
Number of subjects: 1124

Group type: EXPERIMENTAL
Intervention: Intensive renal-replacement therapy
Number of subjects: 1124

Group type: COMPARATOR
Intervention: Less-intensive renal-replacement therapy
Number of subjects: 1124
Study: 17055449

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural approach
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Problem-solving approach
Number of subjects: 48
Study: 15572533

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 696

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 696
Study: 11239191

Group type: EXPERIMENTAL
Intervention: Acupuncture (including electroacupuncture)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (high-intensity, low-frequency)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Subliminal electrostimulation (control group)
Number of subjects: 150
Study: 9225646

Group type: EXPERIMENTAL
Intervention: Laparoscopic treatment
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional conservative abdominal surgery (Laparotomy)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 105
Study: 8120158

Group type: EXPERIMENTAL
Intervention: Pulse-loading (P-L) group received 150 and 200 mg of clomipramine (CMI) on two consecutive evenings, then placebo for 8 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Traditional group began at 50 mg of CMI, followed by gradual increases every second day until 200 mg was reached
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pulse-loading (P-L) group
Number of subjects: 32
Study: 3321413

Group type: EXPERIMENTAL
Intervention: LAF + PSA (decontamination, isolation in a laminar air flow room and prophylactic systemic antibiotics)
Number of subjects: 99

Group type: COMPARATOR
Intervention: PSA (prophylactic systemic antibiotics in a conventional hospital room)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: LAF + PSA
Number of subjects: 99

Group type: COMPARATOR
Intervention: PSA
Number of subjects: 99
Study: 30423420

Group type: EXPERIMENTAL
Intervention: Active tDCS (20 min, 2 mA, anode over left dorsolateral prefrontal cortex, cathode over left temporoparietal cortex)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 48
Study: 27939229

Group type: EXPERIMENTAL
Intervention: NIV in bilevel mode
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham ventilation (continuous positive airway pressure mode, 4 cm H2O)
Number of subjects: 13
Study: 25645191

Group type: EXPERIMENTAL
Intervention: Essential-oil extract of Cretan aromatic plants (0.5ml soft gel capsules, twice a day for 7 days)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (0.5ml olive oil in soft gel capsules)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Essential-oil extract of Cretan aromatic plants
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 23895706

Group type: EXPERIMENTAL
Intervention: Multivitamin/multimineral supplement
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 21809218

Group type: EXPERIMENTAL
Intervention: Cell phone-based counseling intervention for 18 months
Number of subjects: 249

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Cell phone-based counseling intervention with increased exposure
Number of subjects: 249
Study: 19644434

Group type: EXPERIMENTAL
Intervention: Immunosuppressive (IS) drugs
Number of subjects: 26

Group type: COMPARATOR
Intervention: No immunosuppressive (IS) drugs
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: SOF patients
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: MOF patients
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: In vitro LPS stimulation
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Plasma replacement by milieu
Number of subjects: 26
Study: 17451567

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg b.d.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ibuprofen 800 mg t.d.s. plus Omeprazole 20 mg o.d.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 15247521

Group type: EXPERIMENTAL
Intervention: Willingness to pay (WTP) for prevention and cure from JCP in 1998 (non-pollination season)
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Willingness to pay (WTP) for prevention and cure from JCP in 2003 (pollination season)
Number of subjects: 820

Group type: COMPARATOR
Intervention: Comparison of WTP values between 1998 and 2003
Number of subjects: 820
Study: 11559718

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg daily for 4 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg daily for 4 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Letrozole for tumors positive for ErbB‐1 and/or ErbB‐2 and ER
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tamoxifen for tumors positive for ErbB‐1 and/or ErbB‐2 and ER
Number of subjects: 100
Study: 9152671

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 0
Study: 8177688

Group type: EXPERIMENTAL
Intervention: Signed language systems (three different systems)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study: 3665523

Group type: EXPERIMENTAL
Intervention: Calcium entry blocker nicardipine
Number of subjects: 383

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study: 31378952

Group type: EXPERIMENTAL
Intervention: Levodopa Benserazide (LDB) generic preparation (Teva Italia)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Madopar (originator)
Number of subjects: 43
Study: 27935557

Group type: EXPERIMENTAL
Intervention: Wearable tubing assistive walking device (WTAWD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Barefoot
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional elastic band orthosis
Number of subjects: 0
Study: 26477840

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab given monthly
Number of subjects: 2457

Group type: EXPERIMENTAL
Intervention: 0.5 mg or 2 mg intravitreal aflibercept injection given monthly
Number of subjects: 2457

Group type: EXPERIMENTAL
Intervention: 2 mg intravitreal aflibercept given every other month after 3 initial monthly doses
Number of subjects: 2457

Group type: COMPARATOR
Intervention: Capped pro re nata (PRN) regimen
Number of subjects: 2457
Study: 23262496

Group type: EXPERIMENTAL
Intervention: rosuvastatin (10 mg/d)
Number of subjects: 31

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31
Study: 21320764

Group type: EXPERIMENTAL
Intervention: Williams syndrome individuals (WS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal developing individuals (matched for CA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal developing individuals (matched for MA)
Number of subjects: 15
Study: 19850808

Group type: EXPERIMENTAL
Intervention: Knee height +20 cm
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Knee height +10 cm
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Knee height
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Knee height -10 cm
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Knee height -20 cm
Number of subjects: 24
Study: 16118646

Group type: EXPERIMENTAL
Intervention: School-based environmental obesity prevention program
Number of subjects: 450
Study: 12646106

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Cotrimoxazol
Number of subjects: 249

Group type: COMPARATOR
Intervention: Control
Number of subjects: 249